Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190018023 | Thyroid | ATC | regulation of protein localization to nucleus | 87/6293 | 136/18723 | 3.94e-13 | 1.79e-11 | 87 |
GO:007155925 | Thyroid | ATC | response to transforming growth factor beta | 142/6293 | 256/18723 | 4.30e-13 | 1.94e-11 | 142 |
GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
GO:0110053210 | Thyroid | ATC | regulation of actin filament organization | 150/6293 | 278/18723 | 1.82e-12 | 7.58e-11 | 150 |
GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
GO:007156026 | Thyroid | ATC | cellular response to transforming growth factor beta stimulus | 137/6293 | 250/18723 | 3.69e-12 | 1.49e-10 | 137 |
GO:0007044111 | Thyroid | ATC | cell-substrate junction assembly | 65/6293 | 95/18723 | 4.11e-12 | 1.62e-10 | 65 |
GO:0051495111 | Thyroid | ATC | positive regulation of cytoskeleton organization | 125/6293 | 226/18723 | 1.39e-11 | 5.08e-10 | 125 |
GO:0007160111 | Thyroid | ATC | cell-matrix adhesion | 128/6293 | 233/18723 | 1.49e-11 | 5.41e-10 | 128 |
GO:190018222 | Thyroid | ATC | positive regulation of protein localization to nucleus | 60/6293 | 87/18723 | 1.63e-11 | 5.88e-10 | 60 |
GO:190290529 | Thyroid | ATC | positive regulation of supramolecular fiber organization | 117/6293 | 209/18723 | 2.19e-11 | 7.80e-10 | 117 |
GO:000717924 | Thyroid | ATC | transforming growth factor beta receptor signaling pathway | 112/6293 | 198/18723 | 2.42e-11 | 8.44e-10 | 112 |
GO:015011627 | Thyroid | ATC | regulation of cell-substrate junction organization | 51/6293 | 71/18723 | 5.01e-11 | 1.63e-09 | 51 |
GO:0048041110 | Thyroid | ATC | focal adhesion assembly | 59/6293 | 87/18723 | 7.05e-11 | 2.23e-09 | 59 |
GO:000836026 | Thyroid | ATC | regulation of cell shape | 91/6293 | 154/18723 | 7.33e-11 | 2.31e-09 | 91 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:003133428 | Thyroid | ATC | positive regulation of protein-containing complex assembly | 127/6293 | 237/18723 | 1.64e-10 | 4.93e-09 | 127 |
GO:0001952110 | Thyroid | ATC | regulation of cell-matrix adhesion | 78/6293 | 128/18723 | 2.09e-10 | 6.15e-09 | 78 |
GO:005189325 | Thyroid | ATC | regulation of focal adhesion assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
GO:009010925 | Thyroid | ATC | regulation of cell-substrate junction assembly | 47/6293 | 66/18723 | 4.64e-10 | 1.25e-08 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FER | SNV | Missense_Mutation | rs763459582 | c.556G>A | p.Val186Ile | p.V186I | P16591 | protein_coding | deleterious(0.05) | probably_damaging(0.97) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2126N>G | p.Glu709Gly | p.E709G | P16591 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
FER | SNV | Missense_Mutation | rs533871351 | c.362N>C | p.Ile121Thr | p.I121T | P16591 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1598N>A | p.Thr533Lys | p.T533K | P16591 | protein_coding | tolerated(0.97) | benign(0.045) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.281N>G | p.Ser94Cys | p.S94C | P16591 | protein_coding | deleterious(0.01) | possibly_damaging(0.554) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | novel | c.1484N>A | p.Ser495Tyr | p.S495Y | P16591 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-EW-A6SA-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FER | SNV | Missense_Mutation | | c.2207G>A | p.Arg736Lys | p.R736K | P16591 | protein_coding | tolerated(0.19) | probably_damaging(0.97) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
FER | deletion | Frame_Shift_Del | novel | c.1357delN | p.Lys453SerfsTer16 | p.K453Sfs*16 | P16591 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
FER | SNV | Missense_Mutation | novel | c.2332C>T | p.Arg778Trp | p.R778W | P16591 | protein_coding | deleterious(0) | benign(0.267) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
FER | SNV | Missense_Mutation | | c.2207N>C | p.Arg736Thr | p.R736T | P16591 | protein_coding | tolerated(0.07) | probably_damaging(0.993) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 328083505 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ALISERTIB | ALISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | 249565817 | | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | TAMATINIB | R-406 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CENISERTIB | CENISERTIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CYC-116 | CYC-116 | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | LINIFANIB | LINIFANIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | ENTRECTINIB | ENTRECTINIB | |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
2241 | FER | KINASE, DRUGGABLE GENOME, ENZYME, TYROSINE KINASE | | CEDIRANIB | CEDIRANIB | |